Praktické lekárnictvo 3-4/2015

Novel targeted therapeutics in dyslipoproteinemia

Dyslipoproteinemia belongs to the serious risk factors of development of atherosclerosis and cardiovascular diseases as well. The clinical research and development is based on research of molecular processes and their targeting. New medicines were established into the clinical practice during past years: monoclonal antibodies, a type of biologic drug – proprotein convertase subtilisin/kexin type 9 (PCSK9), apolipoprotein B antisense oligonucleotides or orphan medicine inhibiting the microsomal triglyceride transfer proteins. Clinical trials are ongoing with cholesteryl ester transfer protein. The golden standard in dyslipoproteinemia treatment remain statins and fibrates.

Keywords: dyslipoproteinemia, pharmacotherapy, clinical research and development, PCSK9 inhibitors, antisense oligonucleotide of apoB-100, MTP inhibitors, CETP inhibitors.